At a meeting today with the investment community, senior leaders from the Johnson & Johnson Family of Companies (JNJ) will review strategies and opportunities for growth in the Consumer and Medical Device segments. The company will highlight the strategic advantages of its broad base in human health care, its holistic approach to innovation and its strategy to achieve above-market growth across the enterprise. In its hospital medical device businesses, the company holds global leadership positions in Surgery and Orthopedics, as well as key regional leadership positions in China and other emerging markets.
With plans to file more than 20 major new products through 2018, expanding its global presence and implementing novel commercial models, the company expects to deliver above-market growth within the next year. The business is also continuing to accelerate its pace of innovation, and estimates its current pipeline of products – expected to be filed for regulatory approval by 2018 – has greater than $6 billion in sales potential. Johnson & Johnson Vision Care, the global market leader in contact lenses, expects to grow market share and exceed the industry pace of innovation by delivering two new products per year through 2020.
The Johnson & Johnson Diabetes Care Companies, market leader in blood glucose monitoring, are increasing their competitiveness and expect improved market penetration globally to reach more patients. Combined, these businesses have a robust innovation agenda with a current pipeline of products expected to be filed for regulatory approval by 2018, with sales potential greater than $2 billion. The Johnson & Johnson Consumer business competes in categories that total $350 billion globally, and those categories are growing at a weighted average of more than 4 percent. The business has three $1 billion brands today, and expects to expand that to five $1 billion brands by 2020.
The Consumer segment is well positioned to grow sales above the market, while continuing to expand margins to achieve benchmark levels of profitability. With its focus on science-based, professionally endorsed products, the Consumer business expects to accelerate growth with a differentiated innovation pipeline, including more than 100 new products this year.
